Biologic Therapy in Psoriasis (Part I): Efficacy and Safety of Tumor Necrosis Factor- α Inhibitors

Publisher： Bentham Science Publishers

E-ISSN： 1873-4316|18|12|945-963

ISSN： 1389-2010

Source： Current Pharmaceutical Biotechnology, Vol.18, Iss.12, 2018-03, pp. : 945-963

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Tumor Necrosis Factor Inhibitors as Therapeutic Choice in Psoriasis

By  

Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry - Anti-Inflammatory and Anti-Allergy Agents), Vol. 8, Iss. 1, 2009-03 ,pp. : 47-50

Bentham Science Publishers

Access to resources Recommend Favorite

Biologic Therapy in Psoriasis (Part II): Efficacy and Safety of New Treatment Targeting IL23/IL-17 Pathways

By  

Current Pharmaceutical Biotechnology, Vol. 18, Iss. 12, 2018-03 ,pp. : 964-978

Bentham Science Publishers

Access to resources Recommend Favorite

Targeting Tumor Necrosis Factor- in the Therapy of Psoriasis

By  

Current Drug Targets. Inflammation & Allergy, Vol. 3, Iss. 2, 2004-06 ,pp. : 175-183

Bentham Science Publishers

Access to resources Recommend Favorite

Targeting tumor necrosis factor α in psoriasis and psoriatic arthritis

By Fantuzzi Francesca   Del Giglio Micol   Gisondi Paolo   Girolomoni Giampiero  

Expert Opinion on Therapeutic Targets, Vol. 12, Iss. 9, 2008-09 ,pp. : 1085-1096

Informa Healthcare

Access to resources Recommend Favorite

Tumor Necrosis Factor Blockade for Treatment of Inflammatory Bowel Disease: Efficacy and Safety

By  

Current Molecular Pharmacology, Vol. 3, Iss. 3, 2010-11 ,pp. : 145-152

Bentham Science Publishers

Access to resources Recommend Favorite